Business
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
- Net product sales for LIVMARLI® (maralixibat) oral solution totaled $75.1 million for first full fiscal year of U.S. commercial launch, and full year 2022
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Net product sales for LIVMARLI® (maralixibat) oral solution totaled $75.1 million for first full fiscal year of U.S. commercial launch, and full year 2022 revenue totaled $77.1 million\n\n- Conference call to provide business updates today, March 8 at 1:30 p.m. PT/4:30 p.m. ET\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2022 and provided a business update.\n\n“We are proud of our strong commercial, clinical and regulatory execution in 2022 that realized $75.1 million in LIVMARLI net product sales in the first full fiscal year of our U.S. launch and groundbreaking clinical data for our Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) patients,” said Chris Peetz, president and chief executive officer at Mirum. “Building on this foundation, 2023 is poised be a transformative year for Mirum. With our U.S. business positioned to grow 50% year-over-year in net product sales, planned LIVMARLI launches in additional international markets, potential label expansion into PFIC and data milestones for our other late-stage clinical programs, we look forward to deepening our global leadership in rare disease and impacting patients who have been waiting for important new medicines.”\n\nLIVMARLI Alagille syndrome: Strong launch continues fueled by U.S. growth & geographic expansion\n\n\nFourth quarter 2022 net sales grew 48% as compared to third quarter 2022.\n\n\nU.S. business positioned for 50% net product sales growth in 2023.\n\n\nLaunched LIVMARLI in Germany in early 2023 following European Commission approval.\n\n\nApproximately 600 Alagille syndrome patients have received LIVMARLI worldwide to date.\n\n\nPublications highlighting long-term impact:\n\n\nPublished LIVMARLI data highlighting quality of life and sleep improvements in patients with Alagille syndrome in the Journal of Pediatrics.\n\n\nPresented long-term LIVMARLI data demonstrating four-year growth improvement and real-world experience in patients with Alagille syndrome.\n\n\n\n\nLIVMARLI PFIC: Compelling profile emerges from Phase 3 MARCH-PFIC study\n\n\nPresented groundbreaking data from the LIVMARLI Phase 3 MARCH-PFIC study at AASLD, showcasing an unprecedented reduction in pruritus and serum bile acids.\n\n\nFirst study to demonstrat...